AI
Saturday, March 29, 2025 10:24:16 AM
zero82,
Thanks for reposting your free pearls of wisdom and psychic predictions again. Sounds like you really hit the nail on the head with your question🔨
“What happened?” 😶 Thanks for asking…
“What happened” is that the long-committed NWBO leadership team have built a comprehensive worldwide IP patent portfolio, acquired commercial licenses, acquired a novel patent-fortified technology to develop in-house automated manufacturing infrastructure, and trials are already underway with the continuing support of peer-reviewed U.S. government grants.
Both DCVax-L and the Roswell DC technology are being studied in combination with checkpoint inhibitors (and other agents). As efficacy data emerge and further studies commence, big pharma will increasingly view NWBO’s DC platforms as either a complement to their portfolios or a competitor. The results of these combination studies will determine the path forward, as the drugs being paired with NWBO’s DC technologies are already commercialized in a vast and swiftly expanding worldwide immunotherapy market.
Leveraging partnerships with world-renowned research institutions, such as Roswell Park in New York, and peer-reviewed grants from U.S. government agencies, such as the NIH, is both efficient and crucial in supporting the validity of breakthrough science and building value.
The trial that just posted a quality control update on Mar 25, 2025 and is led by Dr. Puzanov as principal investigator is a quite noteworthy example.
https://clinicaltrials.gov/study/NCT04093323
https://physicianresources.roswellpark.org/news/roswell-park-clinical-trials-offer-novel-immunotherapies-for-advanced/metastatic-tumors-refractory-melanoma
NWBO owns three distinct patent-fortified DC product platforms that we currently know about:
1. DCVax-L
2. DCVax Direct
3. Roswell’s DC Platform
✅️ Additionally, we might consider the novel EDEN manufacturing technology, which NWBO acquired through its strategic acquisition of Flaskworks in 2020.
Is is also quite noteworthy that the term “tumor-agnostic” was used in reference to the Roswell DC product platform:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
https://cdmrp.health.mil/bcrp/pbks/2024BCRPProgramBook.pdf
https://clinicaltrials.gov/study/NCT04348747
June 2024
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html
“The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumour microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.
The DC based therapies include versions with tumour antigens loaded into the DCs and versions for intra-tumoural administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The company does not anticipate having to provide any funding or undertake any operational role for these trials.
As previously reported, over time the company has been quietly in-licensing various technologies and IP from various institutions and entities which it believes can be valuable in building a leading franchise in dendritic cell therapies.
The portfolio in-licensed from Roswell Park is complementary to, and builds upon, a portfolio which the company exclusively licensed from another institution last year. Together, the two portfolios encompass more than 20 years of work by one of the foremost groups of dendritic cell experts, led by Dr. Kalinski.
The portfolio in-licensed last year includes the foundational technologies and IP, and positive early-stage clinical trial results, developed by the Kalinski group over 17 years before coming to Roswell. The portfolio in-licensed now includes the further work during the last 7 years at Roswell. Taken together, the company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the company’s own portfolio. The company plans to collaborate with Dr. Kalinski on the further clinical development of the combined technologies.”
⭐️ Combo is King! ⭐️
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
Thanks for reposting your free pearls of wisdom and psychic predictions again. Sounds like you really hit the nail on the head with your question🔨
“What happened?” 😶 Thanks for asking…
“What happened” is that the long-committed NWBO leadership team have built a comprehensive worldwide IP patent portfolio, acquired commercial licenses, acquired a novel patent-fortified technology to develop in-house automated manufacturing infrastructure, and trials are already underway with the continuing support of peer-reviewed U.S. government grants.
Both DCVax-L and the Roswell DC technology are being studied in combination with checkpoint inhibitors (and other agents). As efficacy data emerge and further studies commence, big pharma will increasingly view NWBO’s DC platforms as either a complement to their portfolios or a competitor. The results of these combination studies will determine the path forward, as the drugs being paired with NWBO’s DC technologies are already commercialized in a vast and swiftly expanding worldwide immunotherapy market.
Leveraging partnerships with world-renowned research institutions, such as Roswell Park in New York, and peer-reviewed grants from U.S. government agencies, such as the NIH, is both efficient and crucial in supporting the validity of breakthrough science and building value.
The trial that just posted a quality control update on Mar 25, 2025 and is led by Dr. Puzanov as principal investigator is a quite noteworthy example.
https://clinicaltrials.gov/study/NCT04093323
https://physicianresources.roswellpark.org/news/roswell-park-clinical-trials-offer-novel-immunotherapies-for-advanced/metastatic-tumors-refractory-melanoma
NWBO owns three distinct patent-fortified DC product platforms that we currently know about:
1. DCVax-L
2. DCVax Direct
3. Roswell’s DC Platform
✅️ Additionally, we might consider the novel EDEN manufacturing technology, which NWBO acquired through its strategic acquisition of Flaskworks in 2020.
Is is also quite noteworthy that the term “tumor-agnostic” was used in reference to the Roswell DC product platform:
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
https://cdmrp.health.mil/bcrp/pbks/2024BCRPProgramBook.pdf
https://clinicaltrials.gov/study/NCT04348747
June 2024
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html
“The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumour microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.
The DC based therapies include versions with tumour antigens loaded into the DCs and versions for intra-tumoural administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The company does not anticipate having to provide any funding or undertake any operational role for these trials.
As previously reported, over time the company has been quietly in-licensing various technologies and IP from various institutions and entities which it believes can be valuable in building a leading franchise in dendritic cell therapies.
The portfolio in-licensed from Roswell Park is complementary to, and builds upon, a portfolio which the company exclusively licensed from another institution last year. Together, the two portfolios encompass more than 20 years of work by one of the foremost groups of dendritic cell experts, led by Dr. Kalinski.
The portfolio in-licensed last year includes the foundational technologies and IP, and positive early-stage clinical trial results, developed by the Kalinski group over 17 years before coming to Roswell. The portfolio in-licensed now includes the further work during the last 7 years at Roswell. Taken together, the company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the company’s own portfolio. The company plans to collaborate with Dr. Kalinski on the further clinical development of the combined technologies.”
⭐️ Combo is King! ⭐️
https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
